SHAILY Q4 Results 2026 Preview: Date, Time, Expectations & Key Things To Watch

Shaily Engineering Plastics is navigating a high-growth phase as its healthcare segment, particularly pen injectors for GLP-1 therapies, becomes a primary revenue driver. Investors will be looking for updates on the company's capacity expansion trajectory, the execution of its recent Rs. 423 crore contract, and details regarding the proposed fundraising initiative.

SHAILY Q4 Results Date and Time

The board meeting is scheduled for May 19, 2026, to consider the audited financial results for the quarter and year ended March 31, 2026, recommend final dividend for FY26, and enable fundraising via equity shares, equity-linked securities, or warrants.

What to expect from SHAILY's Q4 FY26 results

In its most recently reported quarter, Shaily Engineering Plastics posted revenue of Rs. 250.5 Cr, PAT of Rs. 37.4 Cr, and an EBITDA margin of 26.5%. The company is scaling its healthcare business, which contributed 31% of revenue in Q1 FY26, with a long-term goal of reaching 50% revenue share within three years. Management continues to monitor competitive intensity in the GLP-1 market, where it currently supplies 30 million units against a planned 80 million unit capacity. The upcoming call will focus on the progress of the Rs. 423 crore pen injector contract signed in February 2026 and the status of capacity additions planned for FY27.

Key Things To Watch

Performance vs Guidance Tracking: Tracking progress against stated operational and financial milestones.

• Revenue Growth — >25% annually — track quarterly
• Healthcare Revenue Share — 50% of total — within 3 years
• Pen Sales Volume — ~30 million pens — FY26
• Effective Capacity — 70-75 million pens — FY27
• EBITDA Margin — Sustain/improve — FY27
• FY26 Capex — Rs. 125 Crores — FY26

Strategic Expansion and Fundraising: Key updates on capital deployment and corporate actions.

• Status of 25M pen capacity completion timeline expected between end of FY26 and beginning of FY27
• Specifics regarding the May 19 board meeting proposal for fundraising via equity or equity-linked securities
• Progress updates on the Rs. 423 crore, 4-year manufacturing and supply agreement signed in February 2026

Risks and headwinds to monitor: Management-flagged operational and market risks.

• Potential price erosion in the GLP-1 market due to end-market competition among customers
• Supply chain constraints regarding machine availability and customization lead times
• Regulatory approval lags for Wegovy compared to Ozempic in Canada and Brazil markets